Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 10/06/2016

DCTD’s Translational Research Program Announces Fiscal Year 2016 SPORE Grantees

The Translational Research Program (TRP) announced its successfully competed FY2016 Specialized Programs of Research Excellence (SPORE) grantees. The SPORE program uses the P50 grant funding mechanism to promote collaborative, interdisciplinary, translational cancer multi-project research. SPOREs are primarily focused on organ site disease, but also on themes that cut across organ sites. Including the 2016 grantees, there are now 54 funded SPOREs located at academic centers in 21 states and one consortium across the country.

FY 2016 SPORE Grantees
Principal Investigator Institution Type of Cancer
James Brugarolas, MD, PhD University of Texas, Southwestern Medical Center Kidney
Paul Harari, MD University of Wisconsin Head/Neck
Anas Younes, MD and
Andrew Zelenetz, MD, PhD
Memorial Sloan-Kettering Cancer Center Lymphoma
*Karen Lu, MD and
Russell Broaddus, MD, PhD
University of Texas, MD Anderson Cancer Center Uterus
*Matthew Philip Goetz, MD and
James Newell Ingle, MD
Mayo Clinic, Rochester Breast
*Christopher Logothetis, MD and
Timothy Thompson, PhD
University of Texas, MD Anderson Cancer Center Prostate
William Hawkins, MD Washington University, St. Louis Pancreas
*Howard Scher, MD Memorial Sloan-Kettering Cancer Center Prostate

*Grant Renewal

The goals of the SPORE program include:

  • Translating novel scientific discoveries from the laboratory and/or population studies to the clinic for testing in humans with cancer or at risk for cancer
  • Determining the biological basis for clinical observations
  • Using specimens from clinical studies to determine correlations between biomarkers and outcomes in patients
  • Promoting collaborations between SPOREs, Cancer Centers, other NCI/NIH funded mechanisms and programs, and outside organizations
  • Promoting pilot projects and career enhancement of researchers new to translational research
  • Supporting research in high incidence and rare cancers
  • Encouraging communication with advocates and advocate organizations to obtain advice from the patient perspective

Contact TRP staff for more information on the SPORE program.